摘要 本研究旨在开发有效的碳酸酐酶抑制剂 (CAI)。目标化合物的设计基于对脲基碳酸酐酶抑制剂 SLC-0111 的结构的修饰。制备了六个系列的具有不同锌结合基团的取代苯甲酰硫脲基核;常规的氨基磺酸基团4a-d和12a-c,其生物等排羧酸基团5a-d和13a-c或羧酸乙酯基团6a-d和14a-c作为潜在的前药。评估了所有化合物对一组四种生理相关的人 CA 同种型 hCA I 和 hCA II、hCA IX 和 hCA XII 的碳酸酐酶 (CA) 抑制活性。化合物4a、4b、4c、4d、5d、12a和12c显示出对hCA I的显着抑制活性,这将突出这些化合物作为治疗青光眼的有希望的候选药物。
Pharmaceutical Compositions For and Methods of Inhibiting Hcv
申请人:Huang Mingjun
公开号:US20080207760A1
公开(公告)日:2008-08-28
The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers.